🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "major milestone" in the battle against drug-resistant strains of the bacteria, according to health experts.

A Global Public Health Issue

Cases of gonorrhoea are on the rise globally, with data suggesting over 82 million new cases each year. Particularly high rates are reported in Africa and countries within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. In England, cases have reached a record high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary development in the context of growing infection rates, the spread of superbugs and the highly restricted available drugs at this time.”

Public health authorities are particularly alarmed about the surge in drug-resistant strains. The global health body has listed it as a "high-priority threat". Recent surveillance revealed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Drugs Secure Approval

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the American regulatory agency in December for combating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Experts anticipate that focused deployment of this new drug will help delay the spread of drug resistance.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, was also approved in concurrent days. This drug, which is additionally indicated for UTIs, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin was the result of a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This milestone marks a significant shift in the treatment of highly resistant gonorrhoea, which previously has been evolving faster than medical innovation.”

Research Study Outcomes and Worldwide Availability

As per results released by a major medical journal, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This places it at an equal footing with the current standard treatment, which combines a dual-drug approach. The research involved hundreds of participants from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, the non-profit has the ability to license and sell the drug in many low-income and middle-income countries.

Doctors on the front lines have voiced optimism. Access to a easy-to-administer therapy like this is seen as a "game-changer" for gonorrhoea control. This is viewed as crucial to reduce the burden of the illness for individuals and to halt the transmission of untreatable gonorrhoea globally.